PTAB IPR Filings Hit Historic Low in Q1 2026: 64% Drop and Discretionary Denial Surge Signal Structural Shift

According to Unified Patents’ Patent Dispute Report for Q1 2026, published April 14, 2026, inter partes review (IPR) petition filings at the Patent Trial and Appeal Board (PTAB) plummeted 66.3% year-over-year and 35.4% quarter-over-quarter in the first quarter of 2026. Total PTAB petitions across all proceedings reached just 131—a historic low—down 64.2% from Q1 2025. Simultaneously, discretionary denials surged 622.7% year-over-year. These figures signal a structural transformation in how the U.S. post-grant review system functions, with significant implications for patent holders and accused infringers alike.

PTAB was established under the America Invents Act (AIA) of 2012 to provide a faster, more cost-efficient mechanism for challenging the validity of issued patents through IPR and post-grant review (PGR) proceedings. In its peak years, PTAB received over 2,000 petitions annually, making it the de facto primary forum for accused infringers—particularly against non-practicing entities (NPEs) asserting questionable patents. The board was widely credited with elevating patent quality by weeding out weak patents, though patent-friendly advocates consistently criticized PTAB as undermining the value of granted rights. That structural debate has now produced a measurable outcome: in Q1 2026, the system is being used at a fraction of its historical pace.

PTAB Petition Collapse

USPTO Pre-Order Procedure

The key data points from the Q1 2026 report are striking. Total PTAB petitions: 131 (down 64.2% YoY, down 32.5% QoQ). IPR petitions: down 66.3% YoY, down 35.4% QoQ. PGR petitions: down 26.3% YoY. Pending petitions across all proceedings: 815, a 12-year low. This represents a collapse in utilization that goes well beyond a cyclical dip. The 815 pending petition figure approaches the earliest years of PTAB’s operation when the institution was still ramping up to its intended scale.

The primary driver of declining filings is the explosive growth of discretionary denials. Q1 2026 discretionary denials rose 622.7% year-over-year, reaching the third-highest level in PTAB history—despite falling 25% from Q4 2025. Discretionary denials are procedural rejections issued before the merits of a petition are considered, allowing PTAB to decline petitions based on factors such as the status of parallel district court proceedings. The NHK-Fintiv framework, established through PTAB’s 2020 precedential decision in Apple Inc. v. Fintiv, empowered the board to deny petitions when a parallel district court case is advancing on a similar schedule. This has created a chilling effect: filers now face meaningful probability of discretionary denial even before substantive evaluation begins, making the cost-benefit calculus far less favorable.

Institution rates have collapsed alongside petition volumes. The institution rate for petitions directed against NPEs fell from 64.6% in Q1 2025 to just 24.6% in Q1 2026—a drop of roughly 40 percentage points. For petitions against operating companies, the rate fell from 81.6% to 40.5% over the same period. An institution rate of less than 25% for NPE-directed petitions means that roughly three in four petitions against NPE patents are being turned away before any substantive review. Given that even a favorable institution ruling does not guarantee cancellation of the challenged claims, the expected return on investment from an IPR petition has diminished dramatically.

Practitioners are pivoting toward ex parte reexamination as a partial substitute. Ex parte reexamination requests rose 157.1% year-over-year in Q1 2026, reaching the second-highest filing volume in USPTO history (trailing only Q4 2025’s all-time record). Unlike IPR, ex parte reexamination does not trigger estoppel against the requester for issues raised in the request, preserving flexibility to raise similar invalidity arguments later in litigation. However, the requester has limited participation rights in the proceeding itself, making it most effective when strong prior art can be presented without requiring active advocacy. Notably, a new USPTO Official Gazette Notice signed by Director Squires and effective April 5, 2026, now allows patent owners to file a 30-page paper arguing against the existence of a substantial new question of patentability before the USPTO decides whether to order reexamination—a procedural development that requesters must now account for in their strategic calculations.

District court patent case filings also declined in Q1 2026, down 21.6% year-over-year and 17.1% quarter-over-quarter. NPEs continued to dominate high-technology patent litigation, accounting for 90.3% of high-tech district court patent cases. Venue concentration in the Eastern and Western Districts of Texas persisted, with those two districts accounting for over 37% of all patent cases and over 57% of all NPE patent cases filed in Q1 2026.

The Q1 2026 data confirms that the IPR system is not simply experiencing a cyclical downturn—it is undergoing a structural realignment. Patent holders benefit from reduced exposure to post-grant review, while accused infringers must recalibrate their defense strategies away from PTAB and toward district court invalidity defenses, ex parte reexamination, and in some cases European post-grant opposition proceedings before the EPO or Germany’s Unified Patent Court. For practitioners, the critical variables in any given matter are now: the status of parallel litigation, the strength of available prior art, the jurisdiction of the district court case, and the technology domain of the patent at issue. Q2 2026 filings will be an important indicator of whether this trend represents a transient inflection point or a durable new equilibrium for U.S. patent challenges.